[go: up one dir, main page]

WO2011103150A3 - Préparations lyophilisées de bendamustine - Google Patents

Préparations lyophilisées de bendamustine Download PDF

Info

Publication number
WO2011103150A3
WO2011103150A3 PCT/US2011/025031 US2011025031W WO2011103150A3 WO 2011103150 A3 WO2011103150 A3 WO 2011103150A3 US 2011025031 W US2011025031 W US 2011025031W WO 2011103150 A3 WO2011103150 A3 WO 2011103150A3
Authority
WO
WIPO (PCT)
Prior art keywords
bendamustine
lyophilized preparations
lyophilized
preparations
cyclodextrins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/025031
Other languages
English (en)
Other versions
WO2011103150A2 (fr
Inventor
Michael L. Cappola
Piyush R. Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cephalon LLC
Original Assignee
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon LLC filed Critical Cephalon LLC
Publication of WO2011103150A2 publication Critical patent/WO2011103150A2/fr
Publication of WO2011103150A3 publication Critical patent/WO2011103150A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur des préparations lyophilisées comprenant de la bendamustine, et des sels pharmaceutiquement acceptables de celle-ci, et des cyclodextrines, ainsi que sur des procédés pour leur production et leur utilisation.
PCT/US2011/025031 2010-02-18 2011-02-16 Préparations lyophilisées de bendamustine Ceased WO2011103150A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30581210P 2010-02-18 2010-02-18
US61/305,812 2010-02-18

Publications (2)

Publication Number Publication Date
WO2011103150A2 WO2011103150A2 (fr) 2011-08-25
WO2011103150A3 true WO2011103150A3 (fr) 2011-11-10

Family

ID=44462002

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/025031 Ceased WO2011103150A2 (fr) 2010-02-18 2011-02-16 Préparations lyophilisées de bendamustine

Country Status (1)

Country Link
WO (1) WO2011103150A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3158991B1 (fr) 2010-01-28 2021-03-17 Eagle Pharmaceuticals, Inc. Formulations de bendamustine
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
WO2012103226A2 (fr) * 2011-01-25 2012-08-02 Dr. Reddy's Laboratories Ltd. Formulations de bendamustine
WO2013102920A1 (fr) * 2011-11-18 2013-07-11 Astron Research Limited Formulation lyophilisée stable de bendamustine
WO2013117969A1 (fr) * 2012-02-06 2013-08-15 Fresenius Kabi Oncology Ltd. Procédé pour préparer des compositions pharmaceutiques stables de composés sensibles à l'hydrolyse
HUE064884T2 (hu) * 2012-03-20 2024-04-28 Eagle Pharmaceuticals Inc Bendamusztin kiszerelések
US20230241218A1 (en) * 2012-07-10 2023-08-03 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
HUE027287T2 (en) 2012-11-19 2016-09-28 Oncotec Pharma Produktion Gmbh A method for preparing a freeze-dried preparation
CN109953954A (zh) 2013-08-27 2019-07-02 V·沃道里斯 苯达莫司汀医药组合物
US9320730B2 (en) 2014-03-13 2016-04-26 Vasilios Voudouris Bendamustine solid dispersions and continuous infusion
CN113679689B (zh) 2015-07-22 2023-09-01 日东电工株式会社 用于纳米粒冷冻干燥物形式的组合物及方法
US10532102B2 (en) 2016-08-19 2020-01-14 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition and methods of uses
US20200246312A1 (en) * 2017-10-05 2020-08-06 Tube Pharmaceuticals Gmbh Oral bendamustine formulations
US11730815B2 (en) 2018-11-26 2023-08-22 Good Health, Llc Stable liquid pharmaceutical compositions comprising bendamustine
EP4134068A4 (fr) * 2020-04-09 2024-02-07 Bika Biotechnology (Guangzhou) Co., Ltd. Composition de bendamustine et son utilisation
GB202219097D0 (en) * 2022-12-16 2023-02-01 Oncopeptides Ab Pharmaceutical preparations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006076620A2 (fr) * 2005-01-14 2006-07-20 Cephalon, Inc. Compositions pharmaceutiques de bendamustine
WO2010036702A1 (fr) * 2008-09-25 2010-04-01 Cephalon, Inc. Formulations liquides de bendamustine
WO2010097700A1 (fr) * 2009-02-25 2010-09-02 Supratek Pharma, Inc. Compositions de cyclopolysaccharide et de bendamustine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
CA2013485C (fr) 1990-03-06 1997-04-22 John Michael Gardlik Produit solide contenant de petites particules de complexes de cyclodextrine
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006076620A2 (fr) * 2005-01-14 2006-07-20 Cephalon, Inc. Compositions pharmaceutiques de bendamustine
WO2010036702A1 (fr) * 2008-09-25 2010-04-01 Cephalon, Inc. Formulations liquides de bendamustine
WO2010097700A1 (fr) * 2009-02-25 2010-09-02 Supratek Pharma, Inc. Compositions de cyclopolysaccharide et de bendamustine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RIBOSEPHARM: "Product monograph ribosepharm passage", PRODUCT MONOGRAPH RIBOSEPHARM, XX, XX, 1 January 2005 (2005-01-01), pages 3 - 73, XP002368437 *

Also Published As

Publication number Publication date
WO2011103150A2 (fr) 2011-08-25

Similar Documents

Publication Publication Date Title
WO2011103150A3 (fr) Préparations lyophilisées de bendamustine
CY1123208T1 (el) Κυκλικα παραγωγα εστερων βορονικου οξεος, μεθοδος για την παρασκευη και θεραπευτικες χρησεις αυτων
WO2010114982A3 (fr) Cakes de lyophilisation d'inhibiteurs du protéasome
WO2012033813A3 (fr) Compositions pour colorer des fibres de kératine
WO2013021279A3 (fr) Anticorps fortement galactosylés
WO2012077136A3 (fr) Procédé de préparation de dérivés de benzimidazole et de leurs sels
WO2012048099A3 (fr) Cellules chargées de nanoparticules
EP2539416A4 (fr) Articles abrasifs, leur procédé de préparation et leur procédé d'utilisation
EP2581104A4 (fr) Tube médical et son procédé de fabrication
WO2011133504A3 (fr) Nanozymes, procédés de production de nanozymes, et procédés d'utilisation de nanozymes
WO2012025944A3 (fr) Sitagliptine, sels et polymorphes de celle-ci
EP2558431A4 (fr) Mélanges de ciment hydraulique et de matières cimentaires supplémentaires à distribution granulométrique serrée, et leurs procédés de fabrication
EP2929015A4 (fr) Préparations de cellules apoptotiques thérapeutiques, méthode de production et utilisations associées
WO2011009938A3 (fr) Stambomycine et dérivés, leur production et leur utilisation comme médicaments
EP3545909B8 (fr) Bourrelet cotyloïdien anti-grippage, auto-centrage
ZA201301463B (en) Pharmaceutical compositions for calonolides,their derivatives and analogues,and process for producing the same
WO2011079193A3 (fr) Préparation de la bendamustine et de ses sels
MX384662B (es) Incremento en la biodisponibilidad de farmacos en la terapia con naltrexona
WO2012087327A3 (fr) Systèmes de polymères
ZA201406382B (en) Levoisovalerylspiramycin i,ii,iii and preparations ,preparation methods and uses thereof
EP2562197A4 (fr) Copolymère comprenant de l'anthracène et du benzosélénadiazole, son procédé de préparation et ses utilisations
AU2011344954A1 (en) Peptide antibiotic over-producing strain, preparation method therefor, and use thereof
WO2010148314A3 (fr) Préparation d'ésoméprazole et de ses sels pharmaceutiquement acceptables
WO2013190509A3 (fr) Préparation d'intermédiaires du bocéprévir
WO2012018791A3 (fr) Préparation de chlorhydrate de prasugrel

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11706683

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11706683

Country of ref document: EP

Kind code of ref document: A2